Related Experiment Videos
Tumour markers in prostatic cancer.
1Department of Chemical Pathology & Immunology, University of Leeds, UK.
Summary
Prostate specific antigen (PSA) is a sensitive tumor marker for prostate cancer detection and monitoring. Elevated PSA levels after treatment indicate residual disease, while specific levels can predict prolonged survival in metastatic cases.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Prostate cancer is a significant health concern for men globally.
- Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
- Comparing PSA assay results requires caution due to the lack of an international standard.
Purpose of the Study:
- To evaluate the efficacy of prostate-specific antigen (PSA) as a tumor marker for prostate cancer.
- To assess the role of PSA in monitoring treatment response and predicting prognosis.
- To explore the utility of PSA in population screening for early prostate cancer detection.
Main Methods:
- Comparative analysis of tumor markers including acid phosphatase, alkaline phosphatase (ALKP), and PSA.
- Monitoring PSA levels post-radical prostatectomy and during hormone manipulation.
- Correlation of PSA levels and scintigram findings with patient survival in metastatic disease.
Main Results:
- PSA demonstrates higher sensitivity and specificity compared to ALKP and acid phosphatase for prostate cancer.
- Post-treatment PSA levels above 0.4 ng/ml suggest residual disease.
- Combined PSA and ALKP reflect tumor activity in metastatic disease; specific PSA thresholds correlate with prolonged survival.
Conclusions:
- PSA is a valuable tool for diagnosing, monitoring, and predicting outcomes in prostate cancer.
- PSA monitoring is crucial for detecting recurrence and assessing treatment effectiveness.
- The role of PSA in population screening, potentially combined with other methods, warrants further investigation.